Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RCOMP
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
RCOMP is a combination chemotherapy regimen used primarily for the treatment of aggressive B-cell non-Hodgkin lymphoma, especially in frail and elderly patients. It consists of rituximab (a monoclonal antibody targeting CD20 on B cells), cyclophosphamide (an alkylating agent), vincristine (a microtubule inhibitor), prednisone (a corticosteroid), and non-pegylated liposomal doxorubicin (Myocet). The substitution of conventional doxorubicin with non-pegylated liposomal doxorubicin aims to reduce cardiotoxicity while maintaining efficacy. This regimen is designed to be less toxic than standard regimens like R-CHOP, making it suitable for patients who may not tolerate standard anthracycline-based therapy[1].
- Brand names
- RCOMP
- Other names
- R-COMPR-COMP 21R-COMP21R-COMP-21
02
Targets
CD20 (B-lymphocyte antigen CD20)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))DNA interstrand cross-linkTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on RCOMP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RCOMP.